INTRODUCTION AND OBJECTIVES: Prostate cancer (PC) is the 2nd leading cause of cancer death among US males and accounts for a great proportion of health expenditures. The objective of this study was to evaluate overall survival (OS) and economic outcomes in chemotherapy-naive metastatic castrate resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
METHODS: A retrospective analysis was performed on 3,174 male patients (!18 years) using the Veterans Health Administration (VHA) database. mCRPC patients with evidence of surgical or medical castration, !1 pharmacy claim for abiraterone acetate or enzalutamide (1st claim date [ index date) following surgical or medical castration and with no chemotherapy treatment during the 12 months pre-index date were identified from 01 April 2014 to 31 March 2017. Patients had continuous VHA enrollment for !12 months pre-and post-index date and were followed until death or disenrollment. Kaplan-Meier analysis was conducted to estimate OS and Cox proportional hazards regression models examined the impact of treatment on survival. Patients initiating abiraterone acetate were 1:1 propensity score matched (PSM) with those initiating enzalutamide. All-cause and PCrelated resource use and costs per-patient-per-month (PPPM) were compared between the matched cohorts during the 12 months postindex date.
RESULTS: This study included 1,945 abiraterone acetate and 1,229 enzalutamide mCRPC patients with mean ages of 73 and 74 years respectively. After a median follow-up of 18 months and 19 months, enzalutamide and abiraterone acetate patients had a median survival time of 30 months and 26 months, respectively. In the Cox analysis, enzalutamide patients had better survival compared to abiraterone acetate patients (HR[0.87; METHODS: Men aged !66 year old with a primary diagnosis of PCa in 2009 (-60 days and þ365 days of continuous follow-up), were identified. High resource spenders, defined as the top 5% of the sum of the total cost incurred for all services rendered per beneficiary within MedPar, Outpatient, and Carrier files for all patients identified. The bivariate relationship of patient and disease characteristics, sociodemographic, as well as regional characteristics associated with being a high resource spender will be examined. The most common and the most costly services rendered according to high resource spending status will be characterized. The odds of being a high resource spender will be assessed via multivariable linear regression model. RESULTS: Overall, 12,875 men with a primary diagnosis of PCa in 2009 were identified. The total cost incurred for all patients was $24,1800,495 (mean $18,781, median $13,408). Of that amount, the top 5% spenders comprised of 646 men who spent a total of $62,474,504, whereas the bottom 95% spenders comprised of 12,229 men who spent a total of $179,325,991. In general, the top 5% spenders of PCa in 2009 were older, sicker at diagnosis, more likely to be Black, and less likely to be married compared to the bottom 95% spenders (all P<0.001 Table 2 ). The top 5% spenders were also more likely to harbour metastatic disease (14% vs. 3%) compared to their 95% counterparts. Of all costs incurred at the inpatient level the average cost of PCa related and non PCa related care among the top 5% spenders was $22,625 and $28,767 vs $13,151 and $13,908 among the bottom 95% spenders, respectively. Of all costs incurred at the Outpatient level, the average cost of PCa related and non PCa related care among the top 5% spenders was $1,418 and $1,011 vs. $1,297 and $770 among the bottom 95% spenders, respectively. The ten most frequent PCa-related procedures for the top 5% and bottom 95% spenders were similar in nature, but differed according to average cost per procedure. After multivariable adjustment, more advanced disease stage, unmarried men, higher CCI, and those living in a high Medicare spending health service area had higher odds of being a top 5% spender than their counterparts.
CONCLUSIONS: The top 5% spenders of PCa account for 25% of all health care cost incurred for all men with a primary diagnosis of PCa in 2009. Artificial insemination is not new; it has been possible in humans for over 200 years. It has become possible for a urologist to procure sperm from a deceased male and use this sperm for posthumous conception, raising complex legal and ethical questions. We seek to highlight these questions and the elusive answers.
Source of
METHODS: Literature review was performed of medical, legal, and ethical texts to identify relevant historical information about the practical application of PMSR.
RESULTS: The most important legal issues surrounding PMSR are the right to govern sperm, the property category of sperm, decedent intent, and inheritance rights. Parpalaix v. CECOS (France, 1984) and Hecht v. Superior Court of California (1993) are the foundational cases in PMSR. They address intent of procreation and the transfer of sperm at death. Emergence of sperm donation led to analysis of the property category of sperm in Davis v. Davis (1992) and the Uniform Anatomical Gift Act (1968) . In Davis v. Davis the court ruled that cryopreserved preembryos held an interim position between other human tissue and persons, not general property. While every situation is different, these important cases set a precedent that in the right circumstance PMSR is legal and provide guiding principles. The Uniform Probate Code (1990) has been used to address inheritance; however, states are encouraged to clarify the issue via legislation.
The chief ethical issue is that of consent of the donor. While consent is often left to proxy or next of kin, PMSR is a special case. Ideal ethical standards suggest "focus on the intent of the decedent and limit any PMSR to specific requests made by the decedent...in writing" When spousal consent is obtained, a 1-year quarantine period to allow bereavement is recommended.
This issue is not unique to the United States. There are full bans on PMSR in many European countries and Canada. The UK allows PMSR, but requires written consent from the deceased. The US has no
